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Gastrointestinal absorption of a drug adminis-
tered orally is affected by multiple parameters
including drug dissolution rate, which is influenced
by the drug solubility in gastrointestinal fluids.
Water solubility of an active pharmaceutical ingre-
dient (API) is the critical factor in the design of
solid oral dosage forms. Nowadays, approximately
40% of the immediate release dosage forms admin-
istered orally contain active substances that are
insoluble in water (1). Therefore, the low dissolu-
tion rate of poorly soluble drugs, i.e., belonging to
the class II and IV of the Biopharmaceutical
Classification System (BCS), still remains one of
the major problems in the formulation of the
dosage forms. Many strategies can be applied to
improve drug dissolution properties, namely:
micronization, formulation of solid dispersions,
complexation with β-cyclodextrins or drug deriva-
tization.
The liquisolid technique that has emerged in
the last decade is a promising approach to the solu-
bility improvement of poorly water soluble drugs.
Its main advantages include simplicity of manufac-
turing, use of commercially available excipients,
and application of well-known methods and equip-
ment utilized for the manufacturing of conventional
tablets.
Liquisolid systems (LCS) are described as dry,
free flowing and compressible powder mixtures
with absorbed solution or dispersion of drug sub-
stance in non-volatile solvent or liquid drug form
(2). The liquisolid system is mainly composed of
two groups of excipients: carriers and coating mate-
rials. Various grades of microcrystalline cellulose
(MCC), dibasic calcium phosphate, pregelatinized
starch and lactose are commonly used as carriers,
while different types of silica dioxide are utilized as
coating material (3). The factor limiting formulation
of reasonable size and low mass liquisolid tablets is
the solubility of the active substance in non-volatile
solvents. Thus, the application of solvents character-
ized by high solubilizing capability could be a prom-
ising method of reducing tablet size and mass. The
most commonly used solvents include propylene gly-
col, polyethylene glycol, polysorbate, CremophorÆ
EL or SynperonicTM PE/L61 (4). 
Insoluble model drug substances such as car-
bamazepine, famotidine, furosemide, piroxicam and
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prednisolone have been used in the liquisolid tech-
nology development (3-7). 
A crucial limitation factor in the application of
LCS technology is the dose of drug substance.
Javadzadeh et al. (6) suggested that the liquisolid
method is suitable for dosages lower than 50 mg.
Nevertheless, it was found that the application of
polymeric additives, e.g., polyvinylpyrrolidone
(PVP) might help to overcome this problem, and
higher amounts of drugs can be used. In that study,
100 mg of carbamazepine was loaded into liquisolid
tablets weighting from 583 mg to 1010 mg per unit,
but there is a lack of information about the size of
the tablets (6). The application of excipients with
high absorption capacity is another possibility to
decrease the mass of the tablets. It was shown that
application of porous excipients such as magnesium
aluminometasilicate instead of conventional tablet-
ing excipients resulted in an increased drug loading
capacity of formulation (3). Despite the low dose of
griseofulvin, 3 mg of the API had to be introduced
in the form of 2 to 5 tablets with a diameter as big as
10 mm (8). The size and the mass of the tablets are
the fundamental factors affecting patient compli-
ance. In the case of liquisolid tablets, the attributes
result from the dose of the API, its solubility in the
solvent used, carrier and coating material absorptiv-
ity and their weight ratio as well as polymer addi-
tives to the formulation. 
The aim of this study was to develop and opti-
mize liquisolid tablets composition characterized by
improved dissolution rate and possible small size
and mass. Furthermore, the influence of various car-
riers and carrier to coating material ratio were stud-
ied in respect to the liquisolid tablets mechanical
properties and model drug dissolution profile.
Furosemide, in the dose of 40 mg which is registered
on the market, was chosen as a model practically
insoluble in water drug substance which belongs to
biopharmaceutical classification system (BCS) class
IV (9). So far, liquisolid formulations containing 20




Furosemide in the form of micronized powder
(J.B. Chemicals and Pharmaceuticals, India) was
used as a model drug. Microcrystalline cellulose of
various grades (VivapurÆ 102 and VivapurÆ 12),
anhydrous dibasic calcium phosphate - Emcom-
pressÆ Anhydrous (JRS Pharma, Rosenberg,
Germany) and spherically granulated anhydrous
dibasic calcium phosphate FujicalinÆ (Fuji
Chemical Industries, Toyama, Japan) were used as
carriers, magnesium aluminometasilicate NeusilinÆ
US2 (Fuji Chemical Industries, Toyama, Japan) as a
coating material, crospovidone - KollidonÆ CL
(BASF, Ludwigshafen, Germany) as a disintegrant
and macrogol 400 (B.D.H. Chemicals) as a drug sol-
vent.
Solubility studies
The solubility studies of furosemide were car-
ried out in PEG 400 or in water. An excess amount
of furosemide was added to 10 mL of solvent and
shaken using a reciprocating shaker (IKA KS 130
BASIC, Germany) at 400 rpm for 24 h in room tem-
perature to reach an equilibrium state. Then, the
samples were centrifuged and filtered through a 0.45
µm Millipore filter, diluted and analyzed spec-
trophotometrically (Jasco V-530 UV/Vis spec-
trophotometer, Japan) at λ = 228 nm. All measure-
ments were done in triplicate. 
Excipients properties
The angle of repose was determined in accor-
dance to Ph. Eur. 8.0 method by pouring the powder
sample from the bottom sieve container mounted 70
mm above a round horizontal surface (60 mm dia.)
until the cone was formed. The angle of repose was
measured using measuring rod connected with the
angular and metric scale. The angle of repose corre-
sponds to the maximum angle between the slope of
the formed cone and the horizontal surface. The
attribute describes frictional forces in loose powder.
Bulk and tapped density were measured according
to the European Pharmacopeia using a W-1 volume-
ter (ZDM Polfa, Poland). Hausner ratio (HR) and
Carrís index (CI) were calculated as follows:
Tapped density ñ Bulk density
CI = ñññññññññññññññññññññññññññ    (Eq.1)
Tapped density
Bulk density
HR = ñññññññññññññññ              (Eq. 2)
Tapped density
The moisture content was analyzed using a
RadWag WPE 30S apparatus at 100OC and 15 s
sampling time till the constant weight of the sample
was achieved.
The flowable liquid retention potential (Φ)
(Eq. 3) corresponds to the maximum amount of liq-
uid that can be absorbed by the excipient, while pre-
serving its good flowability (10). To obtain the
liquisolid powder with good flow properties, the
angle of slide of the excipients with admixture of
increasing amounts of PEG 400 was investigated.
The sample of powder (1.0 g) was placed on a pol-
ished metal plate which was gradually tilted until the
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sample started to slide. In order to check physical
properties of admixed ingredients the samples were
examined 5 min and 24 h after preparation. Values
of Φ were calculated for mixtures which slides
down at the angle of plate inclination of 33O, which
is considered to be optimal flow of the powder.
WliquidΦ = ññññññññññññ                (Eq. 3)
Wpowder
where: Wliquid ñ weight of liquid, Wpowder ñ weight of
dry powder.
Preparation of liquisolid tablets
The composition of tablets is presented in
Table 1. The maximum amount of furosemide solu-
tion (liquid load factor Lf) which can be loaded into
powder bulk was calculated according to equation 4
(10):
Lf = Φcarr. + Φcoat  (1/R)              (Eq. 4)
where:  ñ liquid load factor, Φcarr., Φcoat. ñ flowable
liquid retention potential for carrier and coating
material, respectively, R ñ carrier/coating material
ratio.
Twelve liquisolid formulations with four type of
carriers: FujicalinÆ (LS1 ñ LS3), EmcompressÆ
(LS4 ñ LS6), VivapurÆ 12 (LS7 ñ LS9) and
VivapurÆ 102 (LS10 ñ LS12) were prepared. The
each individual carrier was combined with different
amount of coating material. In particular, the follow-
ing carrier to coating material ratios were examined:
1 : 1, 5 : 1, 10 : 1. Tablets were prepared as follows,
the carrier was placed in a mortar and mixed with
20% furosemide solution in macrogol 400 poured in
the quantity equal to 40 mg dose of the API. The coat-
ing substance (NeusilinÆ US2) was gradually added
and blended gently for 5 min. Then, 5% of KollidonÆ
CL was added and mixing was continued for the next
5 min. Final blends were compressed using a Korsch
EK0 single punch tablet press (Germany). Two lots of
tablets (LS13 and LS14) were prepared using magne-
sium aluminometasilicate in the function of carrier
and coating material. The lots were differentiated by
quantities of disintegrant as follows: 5% for the LS13
formulation and 10% for LS14.
Preparation of directly compressed tablets (DCT)
Control tablets containing 40 mg of crystalline
furosemide were prepared with direct compression
method. The furosemide powder was mixed with
suitable amounts of considered carrier and coating
material. Afterwards, 5% of Kollidon Cl was added
as a disintegrant and mixed. Final blend was com-
pressed using Korsch EK0 (Germany) eccentric
tablet press.
Evaluation of tablet properties
Tablet mass uniformity, thickness and hardness
Ten tablets of each formulation were accurate-
ly weighed and measured. The hardness of the
tablets was evaluated using a VanKel VK 200 hard-
ness tester (USA).
Table 1. Composition of prepared liquisolid tablets calculated on 100 tablets batch.
Coating 20% Kollidon Cl
Form. Carrier (Q) quantity [g] material furosemide amount R Lf
quantity [g] solution [g] [%]
LS1 11.2 11.2 1 1.793
LS2 Fujicalin 33.2 06.6 5 0.602
LS3 44.2 4.4 10 0.453
LS4 11.9 11.9 1 1.678
LS5 Emcompress 41.1 08.2 5 0.487
LS6 59.1 5.9 5% 10 0.338
LS7 12.7 12.7 20.0 1 1.574
LS8 Vivapur 12 52.2 10.4 5 0.383
LS9 85.4 8.5 10 0.234
LS10 13.2 13.2 1 1.510
LS11 Vivapur 102 62.7 12.5 5 0.319
LS12 117.5 11.8 10 0.170
LS13
Neusilin US2
13.4 5% - -
LS14 13.4 10% - -
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Friability
The friability test was performed according to
the European Pharmacopoeia 8.0 using PharmaTest
PTF-E friabilator (Germany). 
Disintegration time
Tablets disintegration time was determined
using a disintegration test ElectroLab ED2 Sapo
(India) apparatus in accordance with Ph. Eur. 8.0
method. Purified water kept at 37OC was used as a
medium, six randomly selected tablets from each
formulation were evaluated. 
Furosemide content determination
Three randomly taken tablets of each formula-
tion were accurately weighed and shaken with 200
mL of sodium hydroxide solution (4 g/L) over 24 h
(IKA KS 130 Basic shaker, Germany). Afterwards,
samples were centrifuged at 3600 rpm and filtered
through 0.45 µm MiliporeÆ filter. After dilution,
drug concentration was assayed spectrophotometri-
cally using a Jasco V-530 UV-Vis spectrophotome-
ter (Japan) with a wavelength λ = 228 nm.
Dissolution studies
Drug dissolution studies were carried out using
a Ph. Eur. 8.0 dissolution apparatus 2 (Hanson
Research SR8 Plus Dissolution Test Station, USA)
operated at 50 rpm. Tablets were placed in 900 mL
of 0.1 mol/L hydrochloric acid solution (pH 1.2) at
37OC. Sample volumes of 5 mL were withdrawn
from each dissolution vessel at 5, 10, 15, 30, 60 and
120 min and analyzed spectrophotometrically at λ =
228 nm. Every time vessel volumes were replen-
Table 2. Excipients parameters.
Excipient Φ value Humidity Angle of Hausner Carr indexcontent (%) repose (O) ratio (%)
Vivapur 102 0.021 4.7 45 1.38 27.7
Vivapur 12 0.085 2.5 38 1.39 28.3
Emcompress Anh. 0.189 0.6 34 1.21 17.0
Fujicalin 0.304 1.1 30 1.14 12.5
Neusilin US2 1.489 7.2 27 1.15 13.3
Table 3. Physical parameters, disintegration time and amount of drug dissolved of each formulation.
Average Amount of API
Form.
Tablet mass Dia. Thickness Hardness Friability
disintegration dissolved after [mg] ± SD [mm] [mm] [N] ± SD [%]
time 2 h [%] ± SD
LS1 439.1 ± 8.6 10 4.07 45.6 ± 7.3 0.78 5 min 11 s 83.11 ± 5.77
LS2 627.7 ± 11.9 11 4.92 38.5 ± 2.4 0.13 1 min 58 s 92.93 ± 10.54
LS3 721.2 ± 6.3 12 4.25 48.4 ± 2.5 0.03 7 min 40 s 91.08 ± 7.29
LS4 463.7 ± 9.5 11 3.60 40.3 ± 5.5 0.31 9 min 07 s 85.17 ± 18.84
LS5 728.7 ± 8.1 11 4.68 51.3 ± 3.2 0.06 5 min 22 s 83.59 ± 14.06
LS6 833.8 ± 14.5 11 5.43 56.7 ± 9.1 0.08 1 min 26 s 84.79 ± 9.59
LS7 476.4 ± 8.7 15 3.74 40.6 ± 0.9 0.15 9 min 18 s 79.11 ± 15.53
LS8 870.0 ± 14.9 15 4.45 53.5 ± 9.3 0.15 29 s 69.27 ± 1.16
LS9 1200.0 ± 13.3 15 6.88 58.3 ± 4.5 0.97 26 s 71.09 ± 2.16
LS10 484.9 ± 5.8 12 3.68 48.2 ± 3.6 0.17 12 min 13 s 52.18 ± 17.66
LS11 1009.0 ± 11.2 15 5.75 53.6 ± 3.3 0.79 31 s 76.21 ± 0.49
LS12 1569.0 ± 34.1 20 4.93 48.5 ± 7.4 0.71 24 s 68.20 ±3.30
LS13 349.7 ± 5.6 10 3.88 36.2 ± 4.0 0.13 14 min 53 s 85.83 ± 6.55
LS14 360.0 ± 6.8 10 4.16 37.2 ± 5.7 0.14 7 min 51 s 95.86 ± 5.66
DCT 460.0 ± 7.1 12 4.21 58.35± 4.2 0.90 52 s 28.53 ± 2.30
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ished automatically with fresh medium. The meas-
urements were carried out in triplicate. There was no
interference on the absorption spectrum of
furosemide from liquid vehicles and other excipi-
ents. 
RESULTS AND DISCUSSION
The solubility of furosemide in macrogol 400
(234.97 mg/mL) was approximately 10000 times
higher than in water (26.9 µg/mL). Javadzadeh et al.
(12) showed that the dissolution rate is directly pro-
portional to the fraction of molecularly dispersed
drug (FM) and the use of drug solution causes that
the FM factor is as high as possible (FM = 1). The
high solubility of furosemide in macrogol 400
allows obtaining small tablets since less amount of
liquid has to be adsorbed onto powder surface.
According to the flowability results obtained
for raw materials it was stated that NeusilinÆ US2
possesses the best flow properties (Table 2). Its flow
characteristic can be expressed as excellent based on
the angle of repose lower than 30O and good accord-
ing to the compressibility index (11-15%) and
Hausner ratio (1.12 ñ 1.18). The results of the liquid
sorption capacity show that the values of flowable
liquid retention potential (Phi, Φ) were correlated
with the angle of repose of raw material and it
increases with lower angle of repose values. The
Phi-values were in the range from 0.021 for
VivapurÆ 102 up to 1.489 for magnesium alumi-
nometasilicate, which corresponds with the highest
angle of repose of VivapurÆ 102 (45O, passable 
flow - may hang up) and the lowest for NeusilinÆ
US2 (27O, excellent flow) from all of tested excipi-
ents. The high humidity content of NeusilinÆ US2 is
due to its large specific surface area reaching up to
300 m2/g (11), but absorbing capacity was not
affected by the humidity content, because Φ-value
was the highest and reached up 1.49. The compari-
son of EmcompressÆ and FujicalinÆ shows better
flow properties of the spherically granulated dibasic
calcium phosphate (FujicalinÆ). The difference
between those excipients is in their specific surface
area and shape. FujicalinÆ is composed of spheri-
cally granulated particles with a porous surface
which results in a high specific surface area, i.e.,
over 32 m2/g while EmcompressÆ Anhydrous has
20.7 m2/g (11) which resulted in approx 1.6-fold
lower liquid sorption capacity. Also the microcrys-
talline cellulose VivapurÆ 12 with a larger particles,
of median size 180 µm, has a higher value of flow-
able liquid retention potential in comparison to
VivapurÆ 102 with an average particle size of 100
µm. Based on the comparison of obtained results it
can be stated that the spherically granulated anhy-
drous dibasic calcium phosphate is the most suitable
carrier. 
The characteristics of all kinds of tablets are
presented in Table 3. Among the evaluated physical
properties such as mass, thickness, hardness, friabil-
ity and disintegration time for liquisolid formula-
tions, the differences has been identified particular-
ly in tablet mass and disintegration time. A relation-
ship between the excipients properties and the
tablets mass and diameter was identified. Tablets
prepared with high absorption capacity substances
such as magnesium aluminometasilicate (LS13,
LS14) and spherically granulated anhydrous dibasic
calcium phosphate i.e. formulations LS1ñLS3 have
the lowest mass among of the studied formulations
prepared with different types of carriers. When
EmcompressÆ was used as a carrier the increase of
tablet mass was estimated while disintegration time
was elongated only for two formulations (LS4,
LS5). Tablets with microcrystalline cellulose PH102
were characterized by the highest mass exceeding
1569 mg and use of punches with 20 mm in diame-
ter (LS12). Similar results were obtained by
Hentzschel et al. while replacing microcrystalline
cellulose and silica with NeusilinÆ US2 causing the
griseofulvin unit dose mass reduction from 2026 to
600 mg (8). 
The tablets parameters also depend on carri-
er/coating material ratio. The increase of NeusilinÆ
US2 amount in the formulation results in the tablet
mass and size decrease due to its high sorption
capacity. For example, the mass of LS1 tablets con-
taining 112 mg of NeusilinÆ US2, with the carrier to
coating ratio 1 : 1, was 439 mg and 10 mm in diam-
eter while in the case of LS3 tablets, in which the
amount of NeusilinÆ US2 was three times lower,
the tablet mass was 721 mg and diameter was 12
mm. The same relationship was identified for tablet
formulations prepared with other carriers. Based on
Ph. Eur. 8.0 monograph all of the tablets met the
pharmacopeial friability requirement because the
loss of weight after the friability test did not exceed
1%. The average disintegration time ranged from 24
s (LS12) to 14 min 53 s (LS13). Compared the aver-
age disintegration times for tablets containing
microcrystalline cellulose with different amount of
NeusilinÆ US2 i.e., LS7 ñ LS12 tablets, it was stat-
ed that high quantity of NeusilinÆ US2 in formula-
tion significantly affect the disintegration time. This
was confirmed by long disintegration times for
tablets composed only with this coating material.
LS13 tablets do not comply with the pharmacopeia
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requirement, despite that the average time was
below 15 min but three of the six tablets had a dis-
integration time over 15 min. Two-fold higher
amount of the disintegrant in the LS14 formulation
with respect to the LS13 tablets resulted in reduction
of disintegration time by half (Table 3).
The effect of the excipients used in tablet for-
mulations on furosemide release profile was investi-
gated. As shown in Table 3, there were large differ-
ences in drug dissolution between fourteen types of
tablets. The amount of furosemide dissolved after 2
h was in the range from 52.18% to 95.86%. Taking
into account tablet formulations prepared with both
kinds of the excipients i.e., carrier and coating mate-
rial (LS1 ñ LS12), the highest amount of the drug
(92.93%) was released from LS2 liquisolid tablets
containing spherically granulated anhydrous dibasic
calcium phosphate (FujicalinÆ) as a carrier. In the
case of EmcompressÆ, independently of excipients
quantity the amounts of furosemide released after 2
h were similar 83.6% ñ 85.2% (formulations LS4 ñ
LS6). The release profiles of furosemide for micro-
crystalline cellulose based formulations varied
depending on the physical properties of the carrier,
and VivapurÆ to NeusilinÆ US2 ratio (Table 3).
The dissolution profiles of furosemide from
tablets with 1 : 1 carrier/coating ratio (LS1, LS4,
LS7) were similar independently from the kind of
the carrier i.e., FujicalinÆ, EmcompressÆ and
VivapurÆ 12. The only exception was the formula-
tion with VivapurÆ PH102 (LS10). This kind of
tablets differs in the physical properties and dissolu-
tion of furosemide. They were characterized by long
disintegration time, exceeding 12 min and the low-
est amount of furosemide dissolved after 2 h
(52.2%). High quantity of NeusilinÆ US2 with its
large specific surface area significantly influenced
furosemide dissolution profile.
From these results it can be assumed that
liquisolid tablets with FujicalinÆ and NeusilinÆ
US2 are recommended to enhance the dissolution
rate of furosemide. Two formulations LS2 and LS14
fully met the formulation expectations. The similar
amount of furosemide was released from both LS2
and LS14 formulations after 2 h i.e., 92.93 and
95.86%, respectively. The mass of LS2 tablets was
627 mg, disintegration time 1 min 58 s. In compari-
son, the mass of the LS14 tablets was the smallest
one i.e., 366 mg but the disintegration time was 4-
fold longer. As it is presented on Figure 1, the
amount of dissolved drug after 2 h from liquisolid
tablets was over 3-times greater than in control
tablets (DCT). 
CONCLUSION
This study showed that liquisolid technique is
a promising strategy in the pharmaceutical technol-
ogy. The formulation of liquisolid tablets enhances
the dissolution rate of furosemide when compared
with direct compressed control tablets. Typically
used dose of furosemide is 40ñ120 mg a day but
there was no study on 40 mg furosemide liquisolid
tablets. The results of investigations demonstrate
that by selection of suitable excipients 40 mg
furosemide tablets with acceptable size and mass
with fast and entire drug dissolution could be pre-
pared. Spherically granulated dibasic calcium phos-
phate (FujicalinÆ) and magnesium aluminometasil-
icate (NeusilinÆ US2) as carrier and coating materi-
Figure 1. Comparison of furosemide dissolution profiles for the best liquisolid tablets and direct compressed control tablets
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al, respectively, are suitable for liquisolid technique.
The optimized formulations LS2 and LS14 showed
86.5 ± 8.6% and 84.3 ± 11.4% drug release within
first 30 min and 92.9 ± 10.5% and 95.9 ± 5.7% after
2 h, respectively. The improvement in the furo-
semide dissolution characteristics from liquisolid
tablets is mainly due to utilization of solution of the
API. It was also stated that the dissolution profiles
are affected by the amount of highly absorptive
excipients such as NeusilinÆ US2. Other physical
parameters such as hardness, friability and disinte-
gration time were also satisfactory. The mass of both
formulations was also reduced. It is an important
factor that should be considered in aspect of patient
compliance.
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